Charles Schwab Investment Management Inc. Boosts Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)

Charles Schwab Investment Management Inc. increased its position in shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) by 327.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 46,406 shares of the company’s stock after acquiring an additional 35,556 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.16% of Telomir Pharmaceuticals worth $191,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the company. Rhumbline Advisers increased its position in shares of Telomir Pharmaceuticals by 105.9% in the fourth quarter. Rhumbline Advisers now owns 8,600 shares of the company’s stock worth $35,000 after purchasing an additional 4,424 shares during the last quarter. Barclays PLC grew its stake in Telomir Pharmaceuticals by 325.1% in the 3rd quarter. Barclays PLC now owns 7,018 shares of the company’s stock worth $45,000 after buying an additional 5,367 shares in the last quarter. State Street Corp grew its stake in Telomir Pharmaceuticals by 99.1% in the 3rd quarter. State Street Corp now owns 36,094 shares of the company’s stock worth $232,000 after buying an additional 17,967 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Telomir Pharmaceuticals by 40.8% in the 4th quarter. Bank of New York Mellon Corp now owns 72,295 shares of the company’s stock worth $298,000 after buying an additional 20,931 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Telomir Pharmaceuticals by 259.8% during the 3rd quarter. Geode Capital Management LLC now owns 238,737 shares of the company’s stock valued at $1,533,000 after buying an additional 172,382 shares in the last quarter.

Telomir Pharmaceuticals Trading Down 15.2 %

NASDAQ TELO opened at $2.74 on Wednesday. The stock has a 50-day moving average of $4.30 and a 200-day moving average of $4.69. The firm has a market cap of $81.55 million and a PE ratio of -4.72. Telomir Pharmaceuticals, Inc. has a 1-year low of $2.73 and a 1-year high of $9.39.

Telomir Pharmaceuticals (NASDAQ:TELO) last announced its quarterly earnings results on Tuesday, February 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). As a group, equities research analysts forecast that Telomir Pharmaceuticals, Inc. will post -0.4 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on TELO shares. Rodman & Renshaw initiated coverage on shares of Telomir Pharmaceuticals in a research report on Friday, February 21st. They issued a “buy” rating and a $15.00 target price for the company. RODMAN&RENSHAW raised Telomir Pharmaceuticals to a “strong-buy” rating in a report on Thursday, February 20th.

Telomir Pharmaceuticals Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.